FDA Schedules Face To Face Meeting With Repros Therapeutics Inc. To Discuss Androxal® Efficacy
Published: Nov 25, 2013
THE WOODLANDS, Texas, Nov. 25, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today reported it has been granted a face to face meeting with the FDA to discuss the pivotal Androxal efficacy studies per the announcement of October 22, 2013. Prior to the meeting, the Agency will have had the final clinical study reports made available.
Help employers find you! Check out all the jobs and post your resume.